Open AccessPancytopenia During Osimertinib Treatment in a Patient with EGFR-Mutated Non-Small Cell Lung Cancer
Author(s) -
Pietro Di Marino,
Cosima Chiapperino,
Francesca Chiara Primavera,
Maria Teresa Di Martino,
Davide Brocco,
Consiglia Carella,
Antonino Grassadonia,
Nicola Tinari,
Michele De Tursi
Publication year - 2022
Publication title -
oncotargets and therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.054
H-Index - 60
ISSN - 1178-6930
DOI - 10.2147/ott.s315385
Subject(s) - osimertinib , pancytopenia , medicine , lung cancer , cancer research , oncology , lung , pathology , bioinformatics , cancer , adenocarcinoma , biology , bone marrow , ros1
Osimertinib is an irreversible tyrosine kinase inhibitor approved for the treatment of metastatic epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC). In clinical trials, osimertinib has exhibited excellent activity and less toxicity compared to gefitinib, erlotinib and standard chemotherapy.